Quadrivalent Meningitis (MCV4)

Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older

Menactra: Conjugated Meningococcal Vaccine (MCV)

Meningococcal vaccination: Vaccination at home for Meningococcal

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine

Recommended Immunization Schedules for Persons Aged 0 Through 18 Years — United States, 2012

Meningitis Vaccine - e7 Health

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study - The Lancet Infectious

Meningococcal Vaccine - Meningococcal Conjugate Vaccine Latest Price, Manufacturers & Suppliers

Public health and economic impact of meningococcal conjugate (MCV4) vaccination in the South African HIV-positive population